OVID
Ovid Therapeutics Inc.
Ovid Therapeutics Inc. (OVID) has 5 SEC Form 4 filings (5 transaction rows) in the rolling window, disclosed by 0 distinct insiders. Most recent filing: Jul 8, 2026.
- Industry:Biotechnology
- CEO:Margaret Alexander
- Employees:23
- HQ:New York City, NY, US
- IPO:2017-05-05
No open-market insider trades for OVID (Ovid Therapeutics Inc.) in the last 365 days.
Why this page may be quiet. Tracefour displays Form 4 open-market purchases (P) and sales (S): the two transaction codes that signal directional conviction. Restricted stock grants, option exercises, gifts, and tax-withholding sales are filed but intentionally not shown: they're disclosure mechanics, not buy/sell decisions.
Many large-cap executives trade through pre-scheduled 10b5-1 plans set months in advance and batch-disclosed each quarter, so the latest filing on EDGAR for a mega-cap can be weeks old without any insider actually choosing to trade in that window.
Related companies
Ovid Therapeutics Inc. is in the Healthcare sector.